Introduction {#S0001}
============

Colorectal cancer (CRC) is the third most common malignancy and the fourth leading cause of cancer-related mortality worldwide.[@CIT0001] The majority of CRC cases are sporadic, but inherited factors contribute to approximately 30--35% of CRC cases.[@CIT0002] Between 5--10% of CRCs are associated with high-risk mutations in known CRC susceptibility genes, predominantly the mismatch repair (MMR) genes (Lynch Syndrome, LS), *APC* (Familial Adenomatous Polyposis, FAP) and *MUTYH* (*MUTYH* - associated Polyposis, MAP).[@CIT0003]--[@CIT0005] Overall, mutation carriers have an increased risk of CRC (lifetime risk 30--70%).[@CIT0006],[@CIT0007] Genetic factors play an important role in CRC risk and predisposition.[@CIT0008],[@CIT0009] The identification of individuals at high risk for CRC, especially those who carry mutations in a CRC susceptibility gene, is important to provide various options for risk management and targeted screening for cancer prevention.[@CIT0010]

While hereditary CRC has been a common indicator for germline genetic evaluation since MMR genes were identified, many additional genes have subsequently been implicated in CRC.[@CIT0011] Patients who performed germline genetic testing for CRC were typically tested for a limited number of genes that were strongly associated with CRC, such as MMR genes, *APC* and *MUTYH*. With the advent of next-generation sequencing (NGS), germline genetic testing for CRC has shifted from a limited number of phenotype-specific gene assessments to broad panels with multiple genes indicating various hereditary cancer syndromes. Since NGS reduces costs and increases the capacity to analyze multiple genes in parallel, there is an opportunity to provide more information on a large number of genes, allowing for more accurate cancer surveillance and tailored prevention options.[@CIT0012],[@CIT0013] The genes included in different panels vary, ranging from well-established cancer susceptible genes with quantifiable risk levels to less well-defined genes that are not traditionally associated with CRC.[@CIT0012],[@CIT0013]

Herein we used NGS with a 73-genes panel associated with various hereditary cancer syndromes to determine the prevalence and spectrum of germline mutations in a consecutive series of 618 CRC patients. This may help to shape a more comprehensive understanding of genetic structure of CRC and generate accurate individualized risk management strategies for mutation carriers.[@CIT0014]

Materials and methods {#S0002}
=====================

Patients and methods {#S0002-S2001}
--------------------

We reviewed the genetic test results and clinical data from a consecutive series of 618 CRC patients evaluated by an NGS hereditary cancer panel between September 2014 and September 2017 at the Sun Yat-sen University Cancer Center (SYSUCC) (Guangzhou, China). All patients submitted a peripheral blood sample, from which germline DNA was isolated for clinical sequencing. Germline DNA was tested for mutations in 73 cancer susceptibility genes using the NGS method (gene list is detailed in [Table 1](#T0001){ref-type="table"}). Patient demographics, medical history, family history (three generation), colonoscopy or resection findings, tumor location, tumor histology and phenotype, MMR status and CRC stage were obtained through review of medical records and through detailed patient inquiries. The SYSUCC ethical review board approved this study, and written informed consents were obtained. Table 1Genes analyzed by a multigene hereditary cancer panelSyndromeAssociated gene(s)Associated cancer spectrumColon cancer susceptibility genesLynch syndrome (LS）*MLH1, MSH2, MSH6, PMS2, EPCAM*Colorectal, endometrial, ovarian, gastric, urothelial, pancreaticobiliary, cutaneous sebaceous neoplasms, brainFamilial adenomatous polyposis (FAP）*APC*Colorectal, small intestine, ampullary, gastric, desmoid, thyroidMUTYH-associated polyposis (MAP）*MUTYH*Colorectal, duodenalJuvenile polyposis syndrome (JPS)*SMAD4, BMPR1A*Colorectal, GastricPeutz--Jeghers syndrome (PJS）*STK11*Colorectal, breast, pancreatic, gastric, small intestine, cervical, ovarianPTEN hamartoma tumor syndrome, Cowden syndrome*PTEN*Colorectal, breast, endometrial, thyroid, renalOligodontia-colorectal Cancer syndrome*AXIN2*Colorectal, breast cancer, neuroblastomaOther cancer susceptibility genesLi-Fraumeni syndrome (LFS）*TP53*Breast, sarcoma, brain, adrenocortical, leukemia, gastricHereditary breast/ovarian cancer*BRCA1, BRCA2*Breast, ovarian, pancreatic, prostate, melanomaHereditary diffuse gastric cancer syndrome*CDH1*Gastric, breastFamilial atypical multiple-mole melanoma syndrome*CDKN2A*Melanoma, pancreaticGorlin syndrome*PTCH1*Skin, brain, breastBloom syndrome*BLM*Leukemia, lymphomaOther genes*ATM*Breast, pancreatic*CHEK2*Breast, prostate, lung, kidney, thyroid*BARD1, BRIP1, MRE11A, NBN, PALB2, RAD50, RAD51C, RAD51, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, ALK, AR, CDC73, CDK4, CDKN1B, CYLD, DICER1, EGFR, EXT1, EXT2, FH, FLCN, HNF1A, HRAS, HSD3B1, KIT, LMO1, MAX, MEN1, MET, MLH3, MPL, NF1, NF2, NTRK1, PDGFRA, PMS1, PRKAR1A, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SMARCB1, SUFU, TMEM127, TSC1, TSC2*

Clinical genetic testing {#S0003}
========================

NGS-based clinical sequencing of germline DNA for mutations was performed at Clinical Laboratory Improvement Amendments (CLIA)-certified commercial genetic testing laboratory (The Beijing Genomics Institute, BGI, Shenzhen, China) using sequencing by synthesis (SBS) in accordance with current practice standards. NGS was performed to detect single nucleotide variations (SNVs), copy number variants (CNV) and insert/deletion mutations (indels) within 20 bp for all exon regions as well as a portion of intronic regions (±10 bp) for all of the genes in the panel. The average depth was more than 300× in all samples and the coverage of the target regions was approximately 99.5%.

IHC and MSI analysis {#S0003-S2001}
--------------------

MMR status were determined by immunohistochemistry (IHC) testing for *MLH1*, *MSH2*, *MSH6* and *PMS2* protein (antibody: Roche, 07862237001, 078622530, 07862245001, 07862261001) expression in tumor tissue. MSI status were tested using the Bethesda consensus panel (mononucleotide repeats BAT25 and BAT26, and dinucleotide repeats D2S123, D5S346, and D17S250) by multiplex fluorescent PCR and capillary electrophoresis. Tumors showing MSI at 0 marker were classified as microsatellite stable (MSS). Tumors showing MSI at 1 marker were classified as low-frequency microsatellite instability (MSI-L). Tumors showing MSI at 2 or more markers were classified as high-frequency microsatellite instability (MSI-H).

Data analysis {#S0004}
=============

The outcomes of clinical genetic testing were analyzed by us with the assistance of 3D Medicines (Shanghai, China) according to the 2015 American College of Medical Genetics and Genomics (ACMG) standards and guidelines[@CIT0015] for variant classification. Genetic variants were classified as pathogenic, likely pathogenic, variants of uncertain significance (VUS), likely benign or benign. Every variant was analyzed by at least a master- or PhD-level analyst and a PhD-level Fellow clinical molecular geneticist. We also referred to specific tools and resources include the Exome Sequencing Project (ESP),[@CIT0016] The 1,000 Genomes Projects, The Exome Aggregation Consortium (Ex AC), The Single Nucleotide Polymorphism Database (dbSNP), ClinVar, SIFT[@CIT0017] and Polyphen.[@CIT0018]

PCR amplification and sanger validation {#S0005}
=======================================

To validate the results of NGS, sequence-specific PCR was used to amplify the target fragment with specific primers designed with PelPrimer. Total PCR volume was 25 μl, including12.5 μl 2×Taq PCR MasterMix (KT201, Tiangen Biotech, Beijing), 1 μl template DNA, 9.5 μl ddH2O, 1 μl PCR Primer F and 1 μl PCR Primer R. The first step in the PCR was performed at 94 °C for 3 min, followed by 30 cycles of denaturation at 94 °C for 30 s, annealing at 55 °C for 30 s, extension at 72 °C for 1 min and a final extension at 72 °C for 5 min. Agarose gel electrophoresis and a DNA purification kit were used to isolate and purify the PCR products. Sanger sequencing with an ABI 3500 (Applied Biosystems 3500) genetic analyzer was used to validate all of the pathogenic and likely pathogenic variants. Finally, the sequences were aligned to the Nucleotide Database with NCBI Blast online software.

Statistical analysis {#S0006}
====================

The primary outcome of this study was the detection of cancer susceptibility gene mutations. Information related to patient numbers and demographics were presented using descriptive statistics. Data for qualitative variables were reported as percentages. The association of mutation status with clinical characteristics was analyzed using the chi-squared test or Fisher's exact test (when cells have an expected count of less than 5) to determine *p*-values (qualitative variables) and level of significance was set at 0.05. Patient age at CRC diagnosis was analyzed as a continuous variable and assessed by the two-sample *t*-test, reported as median and range. Wilson score intervals with continuity correction were used to compute confidence intervals. Statistical analysis was performed using SPSS 20.0.

Site-directed mutagenesis and expression plasmid construction {#S0007}
=============================================================

pcDNA3.1B was kindly provided by Dr Xiao-Feng Zhu (State Key Laboratory of Oncology in Southern China, Cancer Center, Sun Yat-sen University). To analyze protein expression in human cells, human h*MLH1/MSH2/MSH6* cDNA was synthesized by PCR and then cloned into the plasmid pcDNA3.1B by double enzyme digestion (EcoR-I/BamH-I restriction enzyme from NEB) and homologous recombination (CloneExpress II One Step Cloning Kit, C112, Vazyme Biotech, Nanjing). Selected *MLH1* variants were constructed by site-directed mutagenesis using a PCR-based protocol. In addition, eight plasmids were constructed and tagged with Flag protein (N-DYKDDDDK-C): *MLH1*-WT, *MLH1* c.1153C\>T (p.R385C), *MLH1* c.1230_1232delinsTG (p.I411Vfs\*80), *MLH1* c.1573T\>G (p.L525V), *MLH1* c.1713delT (p.F571Lfs\*2), *MLH1* c.1866delT (p.A623Qfs\*14), *MLH1* c.278delG (p.S93Ifs\*15) and *MLH1* c.522delG (p.I176Ffs\*26). pcDNA3.1B (empty vector) used as a negative control and *MLH1*-WT was used as a positive control.

HEK293T cell culture and transfection {#S0008}
=====================================

HEK293T cell line was purchased from the Stem Cell Bank, Chinese Academy of Sciences (Shanghai, China). HEK293T cells were cultured in DMEM with 10% fetal bovine serum (FBS) at 37 °C in a humidified 5% CO~2~ atmosphere. HEK293T cells were transfected at 60--70% confluence with expression plasmids using Lipofectamine 3,000 reagent (L3000015, Invitrogen, Shanghai) according to the manufacturer's instructions. After 48 h, the cells from each group were harvested for western blot.

Western blot analysis and co-immunoprecipitation {#S0009}
================================================

Cells were harvested and washed with phosphate-buffered saline (PBS). The lysates were obtained with RIPA lysis buffer (containing 1 mM PMSF) followed by centrifugation (4 °C, 12,000 g, 15 min). Total protein concentrations in the supernatant were examined using an Enhanced BCA Protein Assay Kit (Beyotime Biotechnology, P0010, China). For co-immunoprecipitation, 1 mg of lysate was incubated with anti-Flag Ab or control mouse IgG overnight at 4 °C with rotation and then for 2 h at 4 °C with 20 μl Protein A/G PLUS-Agarose (Santa Cruz Biotechnology). Immunoprecipitates were collected by centrifugation and washed five times with ice-cold PBS. After the final wash, the supernatant was discarded and the pellet was resuspended in SDS lysis buffer, then boiled in 5× SDS loading dye for 5 min. Western blot was performed according to the standard procedure. Briefly, proteins were normalized to 25 μg/lane and loaded on a 10% SDS-polyacrylamide gel for electrophoresis and then transferred to PVDF membranes. The membranes were blocked with 5% BSA in TBST (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween-20) for 1 h. The membranes were incubated with primary antibodies (anti-*MLH1*, CST3515T, mouse, 1:1,000; anti-*PMS2*, Abcam, ab110638, rabbit, 1:1,000 and anti-β-actin, 60008-1-Ig, Proteintech, mouse, 1:1,000) overnight at 4 °C, then washed three times with TBST for 10 min each time and incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotech) at room temperature for 1 h. After washing the secondary antibody, the bands in the membrane were detected using chemiluminescence ECL kit. Finally, the membranes were processed using an enhanced chemiluminescence detection system.

Results {#S0010}
=======

Clinical characteristics {#S0010-S2001}
------------------------

A total of 77.8% (481/618) CRC patients were from south China in the Pearl River Valley and 12.5% (n=77) of them were from Yangtze River Valley and the rest were from other catchment areas. Patient characteristics including gender, age at CRC diagnosis, family history of cancer, primary tumor site, tumor histological stage, cancer stage, MMR and MSI status are summarized in [Table 2](#T0002){ref-type="table"}. Men accounted for 59.2% (n=366) of patients and 44.7% (n=276) had a family history of cancer. The mean age at CRC diagnosis was 49.8 years and 48.7% (n=301) patients were diagnosed before 50 years old.Table 2Clinical characteristics of 618 CRC patientsCharacteristicsTotal evaluable cohort No. (%)Age at diagnosis*p*-value＜50 (%)≥50 (%）No. of patients618301317Gender0.005\*Male366 (59.2)161 (53.5)205 (64.7)Female252 (40.8)140 (46.5)112 (35.3)Age at CRC diagnosis, yearsMean (SD)49.8 (12.2)39.5(6.9)59.6(6.8)Family history of cancer0.595No323 (52.3)159 (52.8)165 (52.0)Yes276 (44.7)128 (42.5)147 (46.4)Unkonwn19 (3.0)14 (4.7)5 (1.6)Primary tumor site0.647Right sided colon cancer184 (29.8)96 (31.9)88 (27.8)Left sided colon cancer191 (30.9)93 (30.9)98 (30.9)Rectal cancer193 (31.2)86 (28.6)107 (33.7)Multiple primary colorectal cancer41 (6.6)21 (7.0)20 (6.3)Unknown9 (1.5)5 (1.6)4 (1.3)Tumor histological stage0.012\*Well differentiated adenocarcinoma21 (3.4)14 (4.7)7 (2.2)Moderately differentiated adenocarcinoma495 (80.1)224 (74.4)271 (85.5)Poorly differentiated adenocarcinoma71 (11.5)43 (14.3)28 (8.8)Unknown31 (5.0)20 (6.6)11 (3.5)Cancer stage0.02\*019 (3.1)12 (4.0)7 (2.2)I51 (8.2)18 (6.0)33 (10.4)II192 (31.1)84 (27.9)108 (34.1)III228 (36.9)110 (36.5)118 (37.2)IV103 (16.7)61 (20.3)42 (13.3)Unknown25 (4.0)16 (5.3)9 (2.8)MMR status0.062dMMR167 (27.0)88 (29.2)79 (24.9)pMMR344 (55.7)151 (50.2)193 (60.9)Unknown107 (17.3)62 (20.6)45 (14.2)MSI0.173MSS206 (33.3)97 (32.2)109 (34.4)MSI-L6 (1.0)5 (1.7)1 (0.3)MSI-H66 (10.7)35 (11.6)31 (9.8)Unknown340 (55)164 (54.5)176 (55.5)Mutation status0.017\*Yes11266 (21.9)46 (14.5)No506235 (78.1)271 (85.5)[^2][^3]

A total of 82.7% (n=511) CRC patients had tumors with MMR IHC data available, of which 27% (n=167) were MMR deficient (dMMR). The most common pattern of MMR protein loss at all sites was *MLH1*±*PMS2*-. 45% (n=278) patients had tumors with MSI data available, of which 10.7% (n=66) were MSI-H. Most tumor screening results (MSI and IHC) were consistent for each patient, except for 12 patients (2 MSI-H, pMMR and 10 MSS/MSI-L, dMMR).

According to the clinical characteristics analysis by age ([Table 2](#T0002){ref-type="table"}), we found 4 clinical variables (gender, tumor histological stage, cancer stage, mutation status) that showed significant differences between patients younger and older than 50 years old. There were more male patients than females in both groups, and the difference was more significant in patients over 50 years old. 20.3% (n=61) of patients under 50 and 13.3% (n=42) of patients over 50 were diagnosed with CRC at stage IV. Patients under 50 tended to have more poorly differentiated tumor than patients over 50 years. Patients under 50 years old were signiﬁcantly more likely to carry pathogenic or likely pathogenic mutations than patients older than 50 (21.9% vs 14.5%, respectively). LS mutation carriers account for 14.3% (n=43) and non-LS mutation carriers account for 7.6% (n=23) of 301 patients under 50 years old.

Germline findings {#S0011}
=================

Overall, 460 patients carried at least one pathogenic or likely pathogenic or VUS mutation ([Figure 1A](#F0001){ref-type="fig"} and [C](#F0001){ref-type="fig"}). A total of 596 VUS germline variants were detected among 419 patients (67.8%, 95% CI, 63.9--71.4%). The genes most likely to have a VUS variant discovered included *ATM* (n=42), *FANCA* (n=37), and *BRCA2* (n=31) ([Figure 1B](#F0001){ref-type="fig"}). The highest VUS frequency was observed in the *ATM* gene. A total of 97 pathogenic and likely pathogenic germline variants were detected among 112 (18.1%; 95% CI, 15.2--21.4%) of the 618 patients, including 80 (12.9%; 95% CI, 10.5--15.9%) with high-penetrance mutations (one with a concurrent moderate-penetrance mutation) and 19 (3.1%; 95% CI, 1.9--4.8%) with only moderate-penetrance mutations. Additionally, 33 pathogenic or likely pathogenic mutations were newly discovered by our study which were unreported in public data bases ([Table 3](#T0005){ref-type="table"}). They were not listed in ClinVar 20150330, dbSNP 138 databases or other literatures and their frequency in the databases of 1,000 Genomes Projects 2015 Aug, ESP 6500 and Ex AC is 0. The rest of the pathogenic and likely pathogenic germline mutations were detailed in [Table S1](#ST0001). Evidence of pathogenicity were according to the 2015 American College of Medical Genetics and Genomics (ACMG) standards and guidelines.Table 4Clinical characteristics analysis of mutation carriers compared with noncarriersCharacteristicNoncarriersLS mutation carriersNon-LS mutation carriersNo. (%)No. (%)*p*-valueNo. (%)*p*-valueNo. of patients5067042Gender0.4870.666Male296(58.5)44(62.9)26(61.9)Female210(41.5)26(37.1)16(38.1)Age at diagnosisMean ± SD50.5±12.045.3±10.40.001\*49.4±15.40.666\<50 y235 (46.4）43(61.4)0.019\*23 (54.8）0.299≥50 y271 (53.6）27(38.6)19 (45.2）Family history of cancer\<0.001\*0.238Yes211(41.7)44(62.9)21 (50.0)No281(55.5)23(32.9)19 (45.2)Unknown14(2.8)3(4.3)2 (4.8)Primary tumor site\<0.001\*0.122Right sided136(26.9)37(52.9)11 (26.2)Left sided166(32.8)10(14.3)15 (35.7)Rectal176(34.8)7(10.0)10 (23.8)Multiple22(4.3)14(20.0)5 (11.9)Unknown6(1.2)2(2.9)1(2.4)Tumor histological stage0.02\*0.375Well differentiated17(3.4)1(1.4)3(7.1)Moderately differentiated412(81.4)51(72.9)32(76.2)Poorly differentiated52(10.3)15(21.4)4(9.5)Unknown25(4.9)3(4.3)3(7.1)Cancer stage0.023\*0.39015(3.0)1(1.4)3 (7.1)I42(8.3)5(7.1)4 (9.5)II145(28.7)34(48.6)13 (31.0)III198(39.1)18(25.7)12 (28.6)IV86(17.0)9(12.9)8 (19.0)Unknown20(3.9)3(4.3)2 (4.8)MMR status\<0.001\*0.039\*dMMR103(20.4)61(87.1)3(7.1)pMMR309(61.1)5(7.1)30 (71.4)Unknown94(18.6)4(5.7)9 (21.5)MSI\<0.001\*0.242MSS183(36.2)2(2.9)21 (50.0)MSI-L6(1.2)0(0.0)0 (0.0)MSI-H40(7.9)25(35.7)1(2.4)Unknown277(54.7)43(61.4)20(47.6)[^4][^5] Table 3Summary of novel pathogenic germline mutationsGeneTranscript_RefChrChr_startChr_endC_dotP_dotMutation_typeEvidenceCount*APC*NM_000038chr5112174454112174455c.3164_3165delp.I1055Nfs\*4Frameshift1 PVS1+1 PM2+1 PM61*APC*NM_000038chr5112174456112174456c.3166delp.I1056\*Frameshift1 PVS1+1 PM2+1 PM61*ATM*NM_000051chr11108216477108216478c.8431_8432delp.K2811Vfs\*3Frameshift1 PVS1+1 PM2+1 PM61*BARD1*NM_000465chr2215593664215593664c.2069dupp.N690Kfs\*4Frameshift1 PVS1+1 PM2+1 PM61*BLM*NM_000057chr159130854091308540c.2093_2094dupp.Y699Vfs\*19Frameshift1 PVS1+1 PM2+1 PM61*BLM*NM_000057chr159134751691347516c.3678C\>Ap.C1226\*Nonsense1 PVS1+1 PM2+1 PM61*BRCA1*NM_007294chr174124659441246595c.953delinsTGTp.H318Lfs\*24Frameshift1 PVS1+1 PM2+1 PM61*FANCA*NM_000135chr168980640489806405c.3931_3932delp.S1311\*Frameshift1 PVS1+1 PM2+1 PM61*FANCA*NM_000135chr168980641789806417c.3918dupp.Q1307Sfs\*6Frameshift1 PVS1+1 PM2+1 PM62*FANCC*NM_000136chr99786950397869504c.1377_1378delp.S459Rfs\*58Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33703512537035131c.87_93delp.N30Sfs\*4Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33704250037042501c.263_264delp.F88\*Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33704251637042516c.278delp.S93Ifs\*15Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33704589237045901c.309_318delp.L104\*Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33704589437045894c.311delp.L104Wfs\*4Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33705037137050371c.522delp.I176Ffs\*26Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33706731837067321c.1230_1232delinsTGp.I411Vfs\*80Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33708380137083801c.1713delp.F571Lfs\*20Frameshift1 PVS1+1 PM2+1 PM61*MLH1*NM_000249chr33709003637090036c.1926dupp.I643Dfs\*2Frameshift1 PVS1+1 PM2+1 PM61*MSH2*NM_000251chr24763050547630505c.176delp.K59Rfs\*5Frameshift1 PVS1+1 PM2+1 PM61*MSH2*NM_000251chr24769383347693833c.1547delp.S516Mfs\*10Frameshift1 PVS1+1 PM2+1 PM61*MSH2*NM_000251chr24769819247698194c.1751_1752delinsAp.I584Nfs\*6Frameshift1 PVS1+1 PM2+1 PM61*MSH2*NM_000251chr24770216847702168c.1764T\>Ap.Y588\*Nonsense1 PVS1+1 PS1+1 PM2+1 PM61*MSH2*NM_000251chr24770240947702409c.2005delp.G669Afs\*16Frameshift1 PVS1+1 PM2+1 PM61*MSH2*NM_000251chr24770355747703557c.2058dupp.L687Tfs\*12Frameshift1 PVS1+1 PM2+1 PM61*MSH2*NM_000251chr24770795247707982c.2577_2606delinsTp.E859Dfs\*13Frameshift1 PVS1+1 PM2+1 PM61*MSH6*NM_000179chr24802581648025816c.695dupp.P233Afs\*2Frameshift1 PVS1+1 PM2+1 PM61*MSH6*NM_000179chr24802603848026038c.916G\>Tp.G306\*Nonsense1 PVS1+1 PM2+1 PM61*MSH6*NM_000179chr24802631448026314c.1192delp.V398Cfs\*13Frameshift1 PVS1+1 PM2+1 PM61*MSH6*NM_000179chr24802760948027609c.2488dupp.S830Ffs\*17Frameshift1 PVS1+1 PM2+1 PM61*MSH6*NM_000179chr24802767648027677c.2554_2555delp.K852Efs\*5Frameshift1 PVS1+1 PM2+1 PM61*MSH6*NM_000179chr24803068048030680c.3294C\>Ap.C1098\*Nonsense1 PVS1+1 PM2+1 PM61*PTCH1*NM_001083603chr99827906998279069c.33dupp.V12Cfs\*27Frameshift1 PVS1+1 PM2+1 PM61 Figure 1The mutations found in 618 CRC patients. (**A**) Heatmap of genes (mutation frequency \>3%) with germline non-benign variants identified among 618 unselected colorectal cancer patients. Each column represents a patient, and each row represents a gene with multiple germline variants. (**B**) A lollipop diagram of germline non-benign variants of *MLH1*, *MSH2*, *MSH6*, *PMS2* and *APC* genes identified among 618 unselected colorectal cancer patients. (**C**) The number of MUT and VUS variants per gene detected with a multigene panel among 618 unselected colorectal cancer patients. The MUT group includes both pathogenic and likely pathogenic variants. Abbreviations: MUT, mutation; CRC, colorectal cancer  ; VUS, variants of uncertain significance.

Seventy patients (11.3%, 95%CI 9% to 14.2%) carried LS mutations (36 *MLH1*, 23 *MSH2,* 7 *MSH6*, and 3 *PMS2*, 2 deletions of the 3ʹ-end of *EPCAM*, including one patient with both *MSH2* and *EPCAM* mutations) and 42 (6.8%, 95% CI, 5--9.15%) carried non-LS mutations (including one patient with both a LS and a non-LS mutations, *MLH1*/*BLM*). Thirteen patients (2.1%; 95% CI, 1.2--3.7%) carried high penetrance non-LS mutations (7 *APC*, 1 *PTCH1*, 1 *PTEN*, 1 *TP53*, 1 *BRCA1*, 1 *BRCA2* and 1 biallelic *MUTYH*). Twenty patients (3.2%; 95% CI, 2--5.1%) carried mutations in moderate-penetrance genes (5 *ATM*, 3 *BARD1*, 4 *BLM*, 2 *BRIP1*, 1 *CDK4*, 4 *CHEK2* and 1 Monoallelic *MUTYH*). The rest carried mutations in less well-defined genes. The spectrum of pathogenic and likely pathogenic germline mutations is shown in ([Figure 2](#F0002){ref-type="fig"}). 61 (87.1%; 95% CI, 76.5--93.6%) of 70 LS mutation carriers demonstrated MSI-H and/or dMMR (2 pMMR or MSS; 6 had missing MSI/MMR data). All the pathogenic and likely pathogenic mutations detected by NGS were validated by Sanger sequencing or qPCR.Figure 2The identified pathogenic and likely pathogenic germline mutations. There was one patient with both *MSH2* and *EPCAM* mutations and one patient with both *MLH1* and *BLM* mutations.

In the clinical characteristics analysis of mutation carriers compared with noncarriers, LS mutation carriers were significantly younger at CRC diagnosis and more likely to have right-sided, poorly differentiated, early stage, MSI-H, dMMR CRC and family history of cancer compared with noncarriers ([Table 4](#T0003){ref-type="table"}). Non-LS mutation carriers were more likely to be pMMR than noncarriers. Age at CRC diagnosis, gender, primary tumor site, tumor histological stage, cancer stage and family history of cancer was not significantly associated with the presence of a non-LS mutation. However 23 (54.8%) of 42 non-LS mutation carriers and 40 (59.7%) of LS mutation carriers were given a diagnosis of CRC under 50 years old. Eleven (26.2%) of 42 non-LS mutation carriers were given a diagnosis of CRC at age ≥50 years old and lacked a family history of cancer.

Pedigree analysis {#S0012}
=================

Two families that had a typical family cancer history and novel mutations were taken into the study after informed consent. Analysis of the candidate variant was performed in additional family members by using NGS or Sanger sequencing.

In family W, the proband was diagnosed with sigmoid colon cancer at 48 years old (pMMR/MSI unknown) and ovarian cancer at 61 years old. The patient carried 3 mutations of uncertain significance (*MUTYH* c.924+7C\>T, *MLH1* c.T1573G, *EGFR* c.A1703G). The patient's father, mother and 4 siblings were diagnosed with different types of cancer ([Figure 3A](#F0003){ref-type="fig"}).Figure 3Evidence to identify germline variants for pathogenicity. (**A**) Pedigree of family W. (**B**) Pedigree of family T. (**C**) Western-blot analysis of *MLH1* and *PMS2* proteins. (**D**) Characterization of constructed *MLH1* mutated plasmids. Numbers represent age at diagnosis. Minus signs indicate that the individual was confirmed not to carry the specific mutation. Shading indicates that the individual was affected with cancer. The arrow heads indicate the proband for that family.**Abbreviations:**CRC, colorectal cancer; CHOL, cholangiocarcinoma; HC, hepatic cancer; BC, breast cancer; PC, pancreatic carcinoma; OC, ovarian cancer; GC, gastric cancer.

In family T, the proband was diagnosed with ascending colon cancer at 43 years old. Immunohistochemistry showed a lack of staining of *MLH1* and *PMS2* proteins. The MSI status was unknown. The patient carried one novel pathogenic mutation (*MLH1* c.278delG). Eleven family members in 3-generations were diagnosed with CRC ([Figure 3B](#F0003){ref-type="fig"}).

The mutation status of the pedigrees suggests that these novel mutations may be pathogenic (supporting evidence, PP4).

In vitro protein analysis of *MLH1* missense variants {#S0013}
=====================================================

Expression was determined by transient transfection of mutated plasmid (Characterization of constructed *MLH1* mutated plasmids were showed in [Figure 3D](#F0003){ref-type="fig"}) into HEK293T cells, which do not express the endogenous *MLH1* gene due to promoter hyper-methylation.[@CIT0019] The c.1230_1232delinsTG (p.I411Vfs\*80), c.1713delT (p.F571Lfs\*2), , c.278delG (p.S93Ifs\*15) and c.522delG (p.I176Ffs\*26) mutations were novel *MLH1* variants that were unreported in public databases and were classified as pathogenic mutations by our study. The MLH1 c.1866delT (p.A623Qfs\*14) mutation were pathogenic MLH1 variant that has been previously reported. The c.1153C\>T (p.R385C) and c.1573T\>G (p.L525V) mutations were VUS *MLH1* variants that have been previously reported. The c.1230_1232delinsTG, c.278delG and c.522delG variants showed a strong reduction of *MLH1* expression, and the c.1713delT and c.1866delT variants showed protein truncation at approximately 65 kd and 70 kd. PMS2 was not properly co-expressed in the truncated c.1713delT, c.1866delT and c.522delG *MLH1* variants since *PMS2* was destabilized on the protein level in the absence of proper dimerization with the *MLH1* C-terminus, which was absent in these variants. Immunoprecipitation experiment showed that the truncating variants *MLH1* c.1713delT, c.1866delT, c.278delG and c.522delG inhibited the interaction between *MLH1* and *PMS2*. In contrast, we found that the c.1153C\>T and c.1573T\>G variants had no effect on protein expression and interactions ([Figure 3C](#F0003){ref-type="fig"}).

The function analysis suggests that *MLH1* c.1230_1232delinsTG (p.I411Vfs\*80), c.1713delT (p.F571Lfs\*2), c.1866delT (p.A623Qfs\*14), c.278delG (p.S93Ifs\*15) and c.522delG (p.I176Ffs\*26) may be pathogenic (moderate evidence).

Discussion {#S0014}
==========

Using multigene panel testing, we determined the prevalence and spectrum of germline mutations in 73 genes associated with various hereditary cancer syndromes in 618 unselected Chinese CRC patients. One hundred twelve patients (18.1%) carried at least a pathogenic or likely pathogenic germline mutation, most of which were in high-penetrance cancer susceptibility genes. One of every 5 patients with CRC diagnosed younger than 50 years had at least 1 pathogenic or likely pathogenic germline mutation (21.9%). The mutation rate was between Pearlman' (16%)[@CIT0009] and Stoffel's studies (25.1%).[@CIT0020] This differences may due to different testing panels or populations. Therefore, we recommend colon cancer screening in the general population starting at age 50.

The prevalence of LS mutation carriers reported in this study (11.3%) was slightly higher than previous publications.[@CIT0021],[@CIT0022] All the CRC patients in our cancer center were recommended for immunohistochemistry and genetic testing. However practical challenges in implementation and concerns regarding cost-effectiveness may result in certain selection bias, which means the patients who participated in the NGS are not completely random. After all, 44.7% of CRC patients in the cohort had a family cancer history and 46.4% of them were under 50, which was also higher than the previous publications. Therefore the prevalence we found for pathogenic and likely pathogenic mutations probably represents the maximum prevalence. Consistent with prior studies that performed germline LS testing after preselection with MSI/MMR tumor testing,[@CIT0023]--[@CIT0025] 36.5% of dMMR CRC patients (61/167) in the current study had LS mutations and 87.1% of LS mutation carriers (61/70) demonstrated MSI-H and/or dMMR. These results support the current practice of performing systematic MSI/MMR immunohistochemistry for all CRCs to screen for LS.[@CIT0026],[@CIT0027] For screening, immunohistochemistry is almost equally sensitive as MSI. However limiting tumor analysis to patients who fulfill the Bethesda criteria or the Amsterdam II criteria would fail to identify 20% (14/70) of LS cases.

In addition to LS, our study also determined the prevalence and spectrum of other hereditary cancer syndromes found in 618 unselected CRC patients. Among 618 CRC patients, 6.8% (42/618) carried non-LS mutations (one with both LS and non-LS mutations), accounting for 37.5% (42/112) of all positive variants identified in our overall testing population. The large number of non-LS mutations found in this cohort suggests that MMR/MSI testing alone is insufficient to identify cancer risk in unselected CRC patients. Furthermore, 26.2% (n=11) of non-LS mutation carriers in this study also lacked traditional phenotypic characteristics of hereditary CRC risk (age under 50 years or family history of cancer), which made it more difficult to identify non-LS mutations. ATM mutations were found in 0.8% (n=5) of CRC patients in our study which was higher than the estimated 0.37% (455/123136) of general population prevalence in a previous publication[@CIT0028] and raises questions about whether such mutations predispose to CRC. Other moderate genes that were not traditionally associated with CRC, such as CHEK2 and BLM (0.6%, 4/618), also showed a possible link between CHEK2/BLM mutations and CRC risk. These findings further support the hypothesis that the analysis of genes currently excluded from routine molecular diagnostic screens may be predisposed to a wider range of cancers, potentially including CRC.[@CIT0028] While studies support an association with cancer, the magnitude of the risk and complete cancer spectrum for variants in these genes is unclear.[@CIT0029]

In our study, pedigree analysis and western blot analysis also provided some moderate or supporting evidence to identify germline variants for pathogenicity. Families W and T had phenotypes and family histories that were highly specific for CRC with a single genetic etiology. The protein expression and interaction of *MLH1* and *PMS2* were affected by some inframe variants especially those that led to protein truncation or had an impact on the interacting domains which is consistent with previous studies.[@CIT0030],[@CIT0031]

Our study has certain limitations. We could not detect a large deletion (\>20 bp), methylation of *MLH1* or the *BRAF* V600E mutation to confirm that there were no such mutations in the patients who were non-carriers especially non-LS mutation carriers with dMMR. We failed to obtain a comprehensive gene mutation status of the pedigrees due to patient compliance.

In conclusion, the advancements in NGS have led to a refined understanding of the genomics of colorectal cancer. The prevalence and spectrum of germline cancer susceptibility gene mutations have been investigated in previous studies among unselected or high-risk Caucasian, American and Asian populations, yet these conditions among unselected Chinese CRC patients are largely undetermined. Our study is the first to our knowledge to determine the prevalence and spectrum of germline cancer susceptibility gene mutations in unselected CRC patients in Chinese population using an NGS panel of 73 genes. Multigene panel testing facilitated the identification of germline mutations in patients who may have otherwise been missed. Only through extensive testing and the accumulation of large international datasets will sufficient information be generated to provide overwhelming evidence to determine whether a gene is associated with CRC susceptibility. Despite these improvements, further studies are needed to determine the function of various mutations in each gene which will enable us to promote clinical translation.
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Table S1Summary of other detected pathogenic or likely pathogenic germline mutationsGeneTranscript_RefChrChr_startChr_endC_dotP_dotMutation_typeClinvar annotationEvidenceMutation annotationRecurrencyExAC\_ ALLExAC_EAS1000G_ALL1000G_EAS*APC*NM_000038chr5112175799112175802c.4510_4513delp.S1504Afs\*2Frameshift.1 PVS1+1 PM2+1 PM6MUT1\....*APC*NM_000038chr5112174490112174493c.3202_3205delp.S1068Gfs\*57Frameshift.1 PVS1+1 PM2+1 PM6MUT2\....*APC*NM_000038chr5112162891112162891c.1495C\>Tp.R499\*NonsenseMUT1 PM2MUT1\....*APC*NM_000038chr5112116592112116592c.637C\>Tp.R213\*NonsenseMUT1 PM2MUT1\....*ATM*NM_000051chr11108141977108141977c.2922-1G\>TNASplicingLP1 PVS1+1 PM2+1 PM6MUT1\....*ATM*NM_000051chr11108236087108236087c.9023G\>Ap.R3008HMissenseLP1 PM2+1 PP3LP18.24E-060..*ATM*NM_000051chr11108165729108165729c.4852C\>Tp.R1618\*NonsenseMUT1 PM2MUT18.24E-060..*ATM*NM_000051chr11108205807108205807c.8122G\>Ap.D2708NMissenseLP1 PM2+1 PP3LP1\....*BARD1*NM_000465chr2215645386215645386c.1211dupp.Y404\*FrameshiftMUT1 PVS1+1 PM2+1 PM6MUT1\....*BARD1*NM_000465chr2215634013215634013c.1338C\>Ap.Y446\*Nonsense.1 PVS1+1 PM2+1 PM6MUT18.27E-060.0001..*BLM*NM_000057chr159129281691292816c.320dupp.L107Ffs\*36Frameshift.1 PVS1+1 PM2+1 PM6MUT28.25E-060.0001..*BRCA2*NM_000059chr133291160132911601c.3109C\>Tp.Q1037\*NonsenseMUT1 PM2MUT1\....*BRIP1*NM_032043chr175993888759938887c.14G\>Ap.W5\*NonsenseLP1 PVS1+1 PM2+1 PM6MUT1\....*BRIP1*NM_032043chr175987108859871088c.1343G\>Ap.W448\*NonsenseMUT1 PM2MUT13.70E-050.0005..*CDK4*NM_000075chr125814531758145317c.184C\>Tp.R62\*Nonsense.1 PVS1+1 PM2+1 PM6MUT18.24E-060..*CHEK2*NM_007194chr222912101529121015c.542G\>Ap.R181HMissenseMUT(1);VUS(5)1 PM2LP10.00010.0012..*CHEK2*NM_007194chr222909117529091175c.1315C\>Tp.Q439\*NonsenseMUT/LP1 PM2LP1\....*CHEK2*NM_007194chr222909591729095917c.917G\>Cp.G306AMissenseLP(2);VUS(1)1 PM2+1 PP3LP15.77E-050..*CHEK2*NM_007194chr222909592629095926c.909-1G\>ANASplicingLP1 PVS1+1 PM2+1 PM6MUT1\....*EPCAM*NM_002354chr2..exon1_9 del.Deletion.1 PVS1+1 PM2LP1\....*EPCAM*NM_002354chr2..exon8_9 del.Deletion..1 PVS1+1 PM2+PP5MUT1\....*FH*NM_000143chr1241667402241667402c.1048C\>Tp.R350WMissenseLP1 PM2+1 PP3LP12.48E-050..*HNF1A*NM_001306179chr12121437263121437263c.1624-2A\>TNASplicing.1 PVS1+1 PM2+1 PM6MUT18.35E-060.0001..*MLH1*NM_000249chr33705598437055984c.739T\>Cp.S247PMissenseMUT1 PM2+1 PP3MUT1\....*MLH1*NM_000249chr33707032437070324c.1459C\>Tp.R487\*NonsenseMUT1 PM2MUT1\....*MLH1*NM_000249chr33706724237067242c.1153C\>Tp.R385CMissenseLP(1);VUS(6)1 PM2+1 PP3LP13.30E-050.0003..*MLH1*NM_000249chr33705899937058999c.793C\>Tp.R265CMissenseMUT1 PM2+1 PP3MUT9\....*MLH1*NM_000249chr33705358937053589c.676C\>Tp.R226\*NonsenseMUT1 PM2MUT18.27E-060..*MLH1*NM_000249chr33709050837090508c.2103G\>Cp.Q701HMissenseMUT1 PM2MUT1\....*MLH1*NM_000249chr33709049237090492c.2089delp.L697Sfs\*86FrameshiftMUT1 PVS1+1 PM2+1 PM6MUT1\....*MLH1*NM_000249chr33708377537083775c.1684C\>Tp.Q562\*NonsenseMUT1 PM2MUT1\....*MLH1*NM_000249chr33706728137067281c.1192C\>Tp.Q398\*NonsenseMUT1 PM2MUT1\....*MLH1*NM_000249chr33704248837042488c.250A\>Gp.K84EMissenseLP1 PM2+1 PP3LP1\....*MLH1*NM_000249chr33708912337089125c.1852_1854delp.K618delInframe_deletionMUT1 PM2+1 PM4MUT1\....*MLH1*NM_000249chr33708914337089143c.1866delp.A623Qfs\*14FrameshiftMUT1 PVS1+1 PM2+1 PM6MUT1\....*MLH1*NM_000249chr33709044637090446c.2041G\>Ap.A681TMissenseMUT1 PM2+1 PP3MUT2\....*MLH1*NM_000249chr33707027337070276c.1410-2_1411delNAFrameshift.1 PVS1+1 PM2+1 PM6MUT1\....*MLH1*NM_000249chr33708382337083823c.1731+1G\>ANASplicingMUT1 PVS1+1 PM2MUT1\....*MLH1*NM_000249chr33704244537042445c.208-1G\>ANASplicingMUT1 PVS1+1 PM2MUT1\....*MLH1*NM_000249chr33705603637056036c.790+1G\>ANASplicingMUT1 PVS1+1 PM2MUT2..0.00020.001*MSH2*NM_000251chr24769026447690264c.1481C\>Gp.S494\*NonsenseLP1 PM2LP1\....*MSH2*NM_000251chr24770363147703631c.2131C\>Tp.R711\*NonsenseMUT1 PM2MUT1\....*MSH2*NM_000251chr24770226547702265c.1861C\>Tp.R621\*NonsenseMUT1 PM2MUT1\....*MSH2*NM_000251chr24770238847702388c.1984C\>Tp.Q662\*NonsenseMUT1 PM2MUT1\....*MSH2*NM_000251chr24770218147702181c.1777C\>Tp.Q593\*NonsenseMUT1 PM2MUT1\....*MSH2*NM_000251chr24763725447637255c.388_389delp.Q130Vfs\*2FrameshiftMUT1 PM2MUT1\....*MSH2*NM_000251chr24769023547690238c.1457_1460delp.N486Tfs\*10FrameshiftMUT1 PM2MUT2\....*MSH2*NM_000251chr24770545147705451c.2251G\>Ap.G751RMissenseMUT1 PM2+1 PP3MUT1\....*MSH2*NM_000251chr24763727247637272c.408delp.F136Lfs\*38Frameshift.1 PVS1+1 PM2+1 PM6MUT18.24E-060..*MSH2*NM_000251chr24764348947643489c.997T\>Cp.C333RMissenseLP(2);VUS(1)1 PM2+1 PP3LP1\....*MSH2*NM_000251chr24767279747672797c.1386+1G\>TNASplicingLP1 PVS1+1 PM2LP1\....*MSH2*NM_000251chr24764156047641560c.942+3A\>TNASplicingMUT1 PM2MUT1\....*MSH2*NM_000251chr24763958847639588c.687delp.A230Lfs\*16FrameshiftMUT1 PVS1+1 PM2+1 PM6MUT1\....*MSH2*NM_000251chr2..exon1_6 del.DeletionMUT1 PVS1+1 PM2+PP5MUT1\....*MSH2*NM_000251chr2..exon7 del.Deletion..1 PVS1+1 PM2+PP5MUT1\....*MSH6*NM_000179chr24802805348028053c.2931C\>Gp.Y977\*NonsenseMUT1 PM2MUT1\....*MUTYH*NM_012222chr14579862745798627c.458G\>Ap.W153\*NonsenseMUT/LP1 PM2LP14.96E-050.0006..*MUTYH*NM_012222chr14579846745798467c.535C\>Tp.R179CMissenseMUT/LP1 PM2+1 PP3LP18.24E-060..*MUTYH*NM_012222chr14579791445797914c.848G\>Ap.G283EMissenseLP(2);MUT(2);VUS(1)1 PM2+1 PP3LP12.50E-050.0001..*PMS2*NM_000535chr760388136038813c.631C\>Tp.R211\*NonsenseMUT1 PM2MUT18.24E-060..*PMS2*NM_000535chr760266586026658c.1738A\>Tp.K580\*NonsenseMUT1 PM2MUT2\....*PTEN*NM_000314chr108969290589692905c.389G\>Ap.R130QMissenseMUT1 PM2+1 PP3MUT1\....*TP53*NM_000546chr1775775477577547c.734G\>Tp.G245VMissenseLP1 PM2+1 PP3LP18.24E-060.0001..*TSHR*NM_000369chr148160975181609751c.1349G\>Ap.R450HMissenseMUT1 PM2+1 PP3MUT40.00030.00340.00020.001[^6][^7][^8]

[^1]: These authors contributed equally to this work

[^2]: **Notes:** Unknown data were excluded from analysis in each group. The mutation status refers to carrying pathogenic or likely pathogenic mutations. \* Statistical significance.

[^3]: **Abbreviations:** CRC, colorectal cancer; MMR, mismatch repair; dMMR, MMR deficient; MSI, microsatellite instability; MSI-L, low-frequency microsatellite instability; MSI-H, high-frequency microsatellite instability; pMMR, proficient mismatch repair.

[^4]: **Notes:** *p*-values were used for comparisons of mutation carriers to noncarriers. One patient with both an LS and a non-LS mutation (*MLH1/BLM*) was included in the LS carriers group. Unknown data were excluded from analysis in each group. \*Statistical significance.

[^5]: **Abbreviations:**LS, Lynch syndrome; MMR, mismatch repair; dMMR, MMR deficient; MSI, microsatellite instability; MSI-L, low-frequency microsatellite instability; MSI-H, high-frequency microsatellite instability.

[^6]: MUT: pathogenic

[^7]: LP: likely pathogenic

[^8]: VUS: uncertain significance
